G
GUARDANT HEALTH INC
NASDAQ: GH (Guardant Health, Inc.)
Last update: 2 days ago, 4:19AM169.08
6.14 (3.77%)
| Previous Close | 162.94 |
| Open | 163.16 |
| Volume | 1,661,458 |
| Avg. Volume (3M) | 1,956,606 |
| Market Cap | 22,689,888,256 |
| Price / Sales | 19.38 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Guardant Health, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | NA |
| Insider Activity | -4.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.63 |
Select this tab to load the latest available analysis.
|
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AZAR ALEX M II | - | 162.99 | -69 | -11,246 |
| HIDALGO MEDINA MANUEL | - | - | 0 | 0 |
| TARIQ MUSA | - | 158.60 | -116 | -18,398 |
| Aggregate Net Quantity | -185 | |||
| Aggregate Net Value ($) | -29,644 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 160.80 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | Director | 17 Oct 2026 | Option execute | 232 | - | - |
| TARIQ MUSA | Director | 16 Oct 2026 | Sell (-) | 116 | 158.60 | 18,398 |
| TARIQ MUSA | Director | 15 Oct 2026 | Option execute | 250 | - | - |
| AZAR ALEX M II | Director | 14 Oct 2026 | Sell (-) | 69 | 162.99 | 11,246 |
| AZAR ALEX M II | Director | 12 Oct 2026 | Option execute | 137 | - | - |
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |